Dutch Firm Launches Advanced DNA Extraction Kit for Clinical Diagnostics

Dutch Firm Launches Advanced DNA Extraction Kit for Clinical Diagnostics

2024-09-25 bio

Netherlands, Wednesday, 25 September 2024.
CleanNA introduces CE-IVD compliant CleanNGS Dx, enhancing Next-Generation Sequencing accuracy in clinical settings. This innovative kit, designed for nucleic acid cleanup and size selection, meets stringent European safety standards, potentially revolutionizing genetic disorder and cancer mutation detection.

A Leap Forward in Clinical Diagnostics

CleanNA, a Dutch manufacturer specializing in magnetic bead-based nucleic acid extraction kits, has launched a new product, CleanNGS Dx. This kit is CE-IVD compliant, ensuring it meets the rigorous safety, effectiveness, and reliability standards set by the European Union for in vitro diagnostic medical devices. The CE-IVD certification not only facilitates market access within the EU but also guarantees the product’s quality, a critical factor for reliable clinical diagnostics.

The Technology Behind CleanNGS Dx

CleanNGS Dx is a single-component reagent designed for nucleic acid cleanup and double-sided size selection, essential steps in Next-Generation Sequencing (NGS) applications. NGS is increasingly being used in clinical diagnostics due to its ability to identify genetic disorders, detect cancer mutations, and track infectious diseases. By ensuring that nucleic acids are of the right size and purity, CleanNGS Dx enhances the accuracy and quality of sequencing results, making it a valuable tool in modern medical diagnostics.

The Impact on Healthcare

The introduction of CleanNGS Dx is expected to have a significant impact on healthcare, particularly in the fields of genetic disorder diagnosis and cancer mutation detection. The technology behind this kit allows for more precise and reliable sequencing, which is crucial for diagnosing and managing diseases. As NGS technology continues to advance and become more cost-effective, products like CleanNGS Dx will play an increasingly important role in clinical settings.

CleanNA’s Growing Portfolio

CleanNGS Dx is the third CE-IVD compliant product launched by CleanNA within a year, following the Clean Cell Free DNA Kit and Clean Quick Viral DNA/RNA. This expansion reflects CleanNA’s commitment to enhancing diagnostic capabilities through innovative products. Based in Waddinxveen, Netherlands, CleanNA is steadily building its portfolio of nucleic acid extraction kits, all of which are designed to meet stringent safety and quality standards.

The Future of Diagnostics

With the launch of CleanNGS Dx, CleanNA is setting new standards in the field of clinical diagnostics. The company’s use of magnetic beads and an easy bind-wash-elute principle makes their products suitable for automated extraction procedures, further increasing their utility in clinical settings. As the demand for accurate and reliable diagnostic tools grows, CleanNA’s innovations will likely become integral to healthcare systems worldwide.

Bronnen


www.businesswire.com www.afp.com cleanNA CleanNGS Dx